Education
About Us
Working with TipRanks
Follow Us
Grifols SA (GRFS)
NASDAQ:GRFS
GRFS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.79 - $9.96
Previous CloseN/A
Volume119.87K
Average Volume (3M)1.23M
Market Cap
$5.81B
Enterprise ValueN/A
Total Cash (Recent Filing)€1.03B
Total Debt (Recent Filing)€6.29B
Price to Earnings (P/E)29.0
Beta1.22
Next Earnings
May 01, 2025EPS Estimate
0.16Last Dividend Ex-Date
Jun 03, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)0.25
Shares Outstanding261,425,100
10 Day Avg. Volume865,428
30 Day Avg. Volume1,229,369
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.77
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Ownership Overview
―
Insiders
8.52% Mutual Funds
38.09% Other Institutional Investors
52.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GRFS FAQ
What was Grifols SA’s price range in the past 12 months?
Grifols SA lowest stock price was $5.79 and its highest was $9.96 in the past 12 months.
What is Grifols SA’s market cap?
Grifols SA’s market cap is $5.81B.
When is Grifols SA’s upcoming earnings report date?
Grifols SA’s upcoming earnings report date is May 01, 2025 which is in 32 days.
How were Grifols SA’s earnings last quarter?
Grifols SA released its earnings results on Feb 26, 2025. The company reported $0.108 earnings per share for the quarter, missing the consensus estimate of $0.232 by -$0.124.
Is Grifols SA overvalued?
According to Wall Street analysts Grifols SA’s price is currently Overvalued.
Does Grifols SA pay dividends?
Grifols SA pays a Annually dividend of $0.345 which represents an annual dividend yield of N/A. See more information on Grifols SA dividends here
What is Grifols SA’s EPS estimate?
Grifols SA’s EPS estimate is 0.16.
How many shares outstanding does Grifols SA have?
Grifols SA has 261,425,100 shares outstanding.
What happened to Grifols SA’s price movement after its last earnings report?
Grifols SA reported an EPS of $0.108 in its last earnings report, missing expectations of $0.232. Following the earnings report the stock price went up 7.588%.
Which hedge fund is a major shareholder of Grifols SA?
Currently, no hedge funds are holding shares in GRFS
---
Grifols SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
GRFS Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 216.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.42%
Trailing 12-Months
Company Description
Grifols SA
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
---
GRFS Company Deck
---
GRFS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a strong performance in revenue growth and EBITDA improvement, with strategic achievements in innovation and deleveraging. However, significant financial expenses and ongoing challenges in free cash flow generation present concerns. The situation in China also requires careful monitoring.Read More>---
GRFS Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering GRFS
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-13.21%
reiterated a buy rating 8 months ago
Copying Tom Jones's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -13.21% per trade.
---